Skip to main content

Treating Bipolar 1 Disorder

By: 3BL Media

Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder

SOURCE: Alkermes

DESCRIPTION:

Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq

About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Tweet me: .@Alkermes has created a new infographic from findings with @HarrisPoll and @DBSAlliance on what healthcare providers (HCPs) had to say about treating individuals with #bipolar 1 disorder: https://bit.ly/3FPKj8a

KEYWORDS: NASDAQ: ALKS, Alkermes

Text: Treating Bipolar 1 Disorder, Healthcare Professionals Share Perspectives on Providing Care for People Living with Bipolar 1 Disorder

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.17
-0.21 (-0.08%)
AAPL  259.34
-0.03 (-0.01%)
AMD  207.67
+4.50 (2.21%)
BAC  55.06
-0.79 (-1.41%)
GOOG  328.46
-0.68 (-0.21%)
META  647.24
-5.82 (-0.89%)
MSFT  478.76
-0.52 (-0.11%)
NVDA  184.28
-0.58 (-0.31%)
ORCL  201.22
+2.70 (1.36%)
TSLA  448.04
+3.03 (0.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.